Cryoport and Catapult Team up for Gene Therapy Development

CryoPort, Inc., one of the leading global providers of innovative products and services to the fast-growing cell and gene therapy industry, and the Cell and Gene Therapy Catapult, an independent innovation and technology organization specializing in the advancement of cell and gene therapies, announced an additional strategic alliance to support the advancement of cell and gene therapies .

As part of this collaboration, Cryoport Systems will open its first global supply chain logistics centre in the UK, a Good Manufacturing Practice (GMP)-compliant facility located within the bioscience cluster in Stevenage, UK, at the CGT Catapult's large-scale cell and gene therapy Stevenage Manufacturing Innovation Centre as per Pharmabiz. Cryoport's entire, end-to-end supply chain capabilities , including risk mitigation services and logistics assistance, will be made available to CGT Catapult collaborators and the greater UK cell and gene therapy community as part of the cooperation. The parties' collaboration will start in early 2024.

The agreement establishes Cryoport Systems' first UK logistics centre to support future expansion and provide end-to-end supply chain solutions to advanced therapy manufacturers. "The cell and gene therapy industry has become an area of rapid growth in the UK with increasing governmental support, making now the prime opportunity to partner with CGT Catapult to offer advanced therapy manufacturers streamlined solutions for their cold chain logistics needs," said Jerrell Shelton, CEO of Cryoport. “This collaboration represents an important milestone in the building of our global supply chain infrastructure, which will aid in the clinical development and commercialization of cell and gene therapies in the UK.